Q2 EPS Forecast for Assembly Biosciences Boosted by Analyst

Assembly Biosciences, Inc. (NASDAQ:ASMB) – Equities research analysts at HC Wainwright upped their Q2 2027 earnings estimates for shares of Assembly Biosciences in a report issued on Wednesday, September 9th. HC Wainwright analyst P. Trucchio now forecasts that the biopharmaceutical company will post earnings of ($0.83) per share for the quarter, up from their previous estimate of ($0.86). HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Assembly Biosciences’ current full-year earnings is $2.28 per share. HC Wainwright also issued estimates for Assembly Biosciences’ Q3 2027 earnings at ($0.84) EPS, Q4 2027 earnings at $1.67 EPS, FY2027 earnings at $0.05 EPS and FY2029 earnings at ($2.22) EPS.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.52. The business had revenue of $13.37 million during the quarter, compared to the consensus estimate of $8.60 million. Assembly Biosciences had a negative net margin of 0.06% and a negative return on equity of 0.02%.

ASMB has been the topic of several other research reports. Wall Street Zen downgraded Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. Mizuho set a $53.00 price objective on Assembly Biosciences in a research note on Tuesday, September 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a report on Friday, July 17th. UBS Group assumed coverage on shares of Assembly Biosciences in a report on Tuesday, September 1st. They set a “buy” rating and a $52.00 price target for the company. Finally, Guggenheim reaffirmed a “buy” rating and issued a $43.00 price objective on shares of Assembly Biosciences in a report on Thursday, May 28th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Assembly Biosciences currently has an average rating of “Moderate Buy” and an average target price of $45.60.

Assembly Biosciences Stock Down 7.3%

Shares of ASMB stock opened at $30.46 on Friday. The company has a market cap of $620.17 million, a P/E ratio of 29.86 and a beta of 1.13. The business has a 50 day moving average of $29.73 and a two-hundred day moving average of $28.38. Assembly Biosciences has a 52 week low of $20.23 and a 52 week high of $39.71.

Hedge Funds Weigh In On Assembly Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Informed Momentum Co LLC raised its position in shares of Assembly Biosciences by 1.6% during the 4th quarter. Informed Momentum Co LLC now owns 29,523 shares of the biopharmaceutical company’s stock worth $1,004,000 after buying an additional 451 shares in the last quarter. ADAR1 Capital Management LLC boosted its holdings in shares of Assembly Biosciences by 4.2% in the fourth quarter. ADAR1 Capital Management LLC now owns 19,747 shares of the biopharmaceutical company’s stock valued at $672,000 after acquiring an additional 800 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Assembly Biosciences by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 131,307 shares of the biopharmaceutical company’s stock valued at $4,468,000 after acquiring an additional 1,212 shares during the period. Arrowstreet Capital Limited Partnership increased its stake in shares of Assembly Biosciences by 4.3% during the first quarter. Arrowstreet Capital Limited Partnership now owns 39,446 shares of the biopharmaceutical company’s stock valued at $1,095,000 after acquiring an additional 1,634 shares during the period. Finally, Bank of America Corp DE raised its holdings in Assembly Biosciences by 6,382.7% during the third quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 3,319 shares in the last quarter. 19.92% of the stock is owned by institutional investors.

Key Headlines Impacting Assembly Biosciences

Here are the key news stories impacting Assembly Biosciences this week:

• Positive Sentiment: Analysts raised long-term earnings estimates. HC Wainwright increased its FY2028 EPS forecast to $0.84 from $0.80 and its FY2030 forecast to $3.32 from $3.28. The firm maintained a Buy rating and a $50 price target, implying confidence in Assembly Biosciences’ longer-term growth prospects. MarketBeat analyst estimates
• Positive Sentiment: Gilead partnership economics could improve program funding. Assembly exercised an option to share U.S. development costs and profits for its herpes program with Gilead. Cost-sharing may reduce Assembly’s financial burden while preserving participation in potential commercial upside. Assembly exercises option with Gilead
• Neutral Sentiment: Management will present at the H.C. Wainwright Global Investment Conference on September 16. The presentation could provide updates on the company’s viral- and liver-disease programs, but the announcement itself does not include new clinical or financial data. Assembly conference presentation announcement
• Neutral Sentiment: Short-interest data offers no meaningful signal. Reported short interest was zero shares as of September 10, unchanged from the prior period, with a zero-day short-interest ratio. The accompanying claim of a “large increase” appears inconsistent with the figures and should not be interpreted as evidence of significant short selling.
• Negative Sentiment: No immediate catalyst accompanied the positive analyst revisions. With the conference still several days away and no new trial results or regulatory decision disclosed, investors may be taking profits or waiting for additional evidence before assigning greater value to the pipeline.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.